Endometrial cancer
Conditions
Interventions
Group of advanced stage without deep myometrial invasion:None
Group of advanced stage with deep myometrial invasion:None
Group of IA3 Stage:None
Group of Extended IA3 Group:None
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.[Age and Sex] Age =18 years, female sex, and absence of disorders of sex development (DSD). 2.[Informed Consent] Possesses full capacity for civil conduct, is able to fully understand and voluntarily sign the informed consent form, or is able to fully understand and voluntarily provide oral informed consent. This criterion may be waived if exemption from informed consent is approved by the Ethics Review Committee. 3.[Pathological Tissue Specimens] Has previously undergone invasive procedures such as surgery, and has sufficient residual pathological tissue specimens stored at the research hospital for study purposes, with a pathological diagnosis of endometrioid carcinoma. 4.[Clinical Data] Has complete clinical data or the data can be supplemented and completed through follow-up. 5.[Grouping] Meets all basic criteria and conforms to the FIGO 2023 Stage IA3 criteria; OR meets all basic criteria, presents with fallopian tube involvement or bilateral ovarian involvement, but fulfills all other specified criteria for FIGO 2023 Stage IA3; OR meets all basic criteria, presents with adnexal involvement and involvement of sites beyond the adnexa, but without deep myometrial invasion, regardless of LVSI status; OR meets all basic criteria, presents with adnexal involvement and involvement of sites beyond the adnexa, and with deep myometrial invasion, regardless of LVSI status.
Exclusion criteria
Exclusion criteria: 1.Pathological diagnosis, upon review, does not meet the aforementioned inclusion criteria. This includes, but is not limited to, non-endometrioid histological types (e.g., serous carcinoma, clear cell carcinoma, carcinosarcoma, etc.). 2.Presence of a concurrent malignancy in another organ system (except for non-melanoma skin cancer). 3.History of organ transplantation prior to the generation of the tissue specimen. 4.Severe lack of baseline clinical data (including pathological information), making it impossible to complete group assignment or basic analysis. 5.Inability to follow up and unknown survival status leading to missing follow-up information, which precludes completion of survival analysis. (Such cases will be excluded from the clinicopathological prognosis study but may be retained in the molecular mechanism study.); 6.Tissue specimen quality does not meet the requirements for omics analysis. (Such cases will be excluded from the molecular mechanism study but may be retained in the clinicopathological prognosis study.); 7.Any other circumstances deemed necessary for exclusion by the investigators following discussion, for purposes such as protecting the scientific integrity and rationale of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival period;Overall survival period; | — |
Countries
China
Contacts
Public ContactShi Xiaohua
Peking Union Medical College Hospital
Outcome results
None listed